Table 1.
Inhibitory effects of compounds against GSK-3β.
| Compd. | GSK-3β IC50 (nM)a | Compd. | GSK-3β IC50 (nM)a |
|---|---|---|---|
| 16a | 4.4 ± 0.2 | 18d | 99 ± 4.8 |
| 16b | 3.1 ± 0.1 | 18e | 64 ± 2.7 |
| 16c | 36 ± 1.7 | 18f | 113 ± 8.6 |
| 16d | 1394 ± 55.2 | 18g | 105 ± 5.2 |
| 16e | 33 ± 1.6 | 18h | 94 ± 3.5 |
| 17a | 20 ± 1.1 | 18i | 173 ± 6.8 |
| 17b | 14 ± 0.6 | 18j | 15 ± 0.3 |
| 17c | 37 ± 1.3 | 18k | 107 ± 6.1 |
| 17d | >5000 | 18l | 158 ± 8.9 |
| 18a | 84 ± 3.2 | 18m | 387 ± 21.2 |
| 18b | 64 ± 2.3 | 18n | 195 ± 10.4 |
| 18c | 153 ± 6.6 | AR-A014418 | 138.8 ± 7.9 |
aThe IC50 values are shown as the mean ± SD from two separate experiments.